🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06016608
Recruiting Observational

An Imaging Study of Polyvascular Disease

NCT06016608 · tracked via the Priya Life Science China tracker
Sponsor
Harbin Medical University
Phase
Observational
Started
2023-10-18
Last updated
2024-12-27

Condition(s) studied

Polyvascular Disease

Investigational drug(s) / intervention(s)

Magnetic Resonance Angiography, Ocular OCTA, CT Angiography

Magnetic Resonance Angiography, Ocular OCTA, CT Angiography: Magnetic Resonance Angiography of intracranial artery, carotid artery, renal artery and lower extremity artery, CT angiography of coronary artery or intracranial artery

Study summary

1. Establish a multimodality imaging database for PVD, improve the one-stop screening process for early PVD based on artificial intelligence, build a full-cycle control information platform, and promote the construction and standardization of a multidisciplinary co-morbidity and co-management diagnosis and treatment model.
2. Based on non-invasive, zero-contrast ocular OCTA combined with one-stop CTA imaging of the heart and brain, construct an integrated "eye-heart-brain" early warning model for PVD, and explore a potential non-invasive and convenient early warning system for PVD.
3. Based on the multi-omics, investigate EVs-mediated intercellular communication network, elucidate the roles and regulatory mechanisms of EVs in the development of PVD, search for potential targets for intervention, and construct an artificial intelligence-based "pan-vascular score" risk assessment system based on the combination of multi-modality imaging and multi-omics biomarkers.

Eligibility

Sex
ALL
Min age
18 Years
Max age
Healthy volunteers
No
Inclusion Criteria: Task 1: 1. Patients with coronary artery disease (≥50% stenosis in any coronary artery on coronary angiography) 2. Age ≥18 years old 3. Proposed OCT-IVUS integrated imaging system 4. able to provide written informed consent prior to the start of any procedures related to the study. Task 2: 1. patients with coronary artery disease (coronary angiography reveals ≥50% degree of stenosis in any coronary artery) and patients with stroke or TIA (confirmed by a neurologist) 2. Age ≥ 18 years 3. able to provide written informed consent prior to the start of any procedures related to the study. Exclusion Criteria: Task 1: 1. severely tortuous/calcified coronary arteries with anticipated difficulty in completing the OCT-IVUS integrated imaging system 2. uncontrolled congestive heart failure or acute left heart failure;plan 3. claustrophobia; 4. left main stem occlusion; 5. proposed coronary artery bypass grafting (CABG); 6. uncontrolled severe ventricular arrhythmia; 7. active bleeding or severe bleeding tendency; 8. acute stroke; 9. patients with hemodynamic instability or unstable cardiac electrical activity (including shock) ; 10. severe renal insufficiency and/or anuria, except in cases where dialysis treatment has been planned; 11. contraindications to the application of contrast media; 12. patients who are severely uncooperative due to psychiatric or serious systemic illness; 13. Patients who, in the opinion of the investigator, are unsuitable for participation in the study. Task 2: 1. patients who are unable to comply with the follow-up schedule; 2. uncontrolled congestive heart failure or acute left heart failure; 3. patients with a life expectancy of less than 6 months; 4. left main stem occlusion; 5. proposed coronary artery bypass grafting (CABG); 6. uncontrolled severe ventricular arrhythmia; 7. active bleeding or severe bleeding tendency; 8. patients with hemodynamic instability or unstable cardiac electrical activity (including shock) ; 9. severe renal insufficiency and/or anuria, except in cases where dialysis treatment has been planned; 10. contraindications to the application of contrast media; 11. patients who are severely uncooperative due to psychiatric or serious systemic illness; 12. patients who, in the opinion of the investigator, are not suitable for participation in the study.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
The Second Affiliated Hospital of Harbin Medical University Harbin Heilongjiang Recruiting

More Harbin Medical University trials in China

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06016608 on ClinicalTrials.gov ↗ ← All trials in China